XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05005728 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

COMBINATION_PRODUCT: vudalimab + carboplatin + cabazitaxel
COMBINATION_PRODUCT: vudalimab + olaparib
BIOLOGICAL: vudalimab monotherapy
COMBINATION_PRODUCT: vudalimab + docetaxel
COMBINATION_PRODUCT: vudalimab + cabazitaxel or docetaxel

Sponsor

Xencor, Inc.